Clinical Trials Logo
  1. Home
  2. Opioid-induced Constipation
  3. NCT01993940

Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

Opioid-induced Constipation Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Naldemedine in the Treatment of Opioid-induced Constipation in Subjects With Non-malignant Chronic Pain Receiving Opioid Therapy

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of naldemedine in the treatment of opioid-induced constipation (OIC) in subjects with non-malignant chronic pain who are not using laxatives

Clinical Trial Description

This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of naldemedine 0.2 mg once daily versus placebo for the treatment of subjects with non-malignant chronic pain and OIC. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01993940
Study type Interventional
Source Shionogi Inc.
Contact
Status Completed
Phase Phase 3
Start date November 2013
Completion date December 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT01965652 - Long Term Safety of Naldemedine Phase 3
Completed NCT04173858 - Evaluation of the Quality of Life of Patients With Opioid-induced Constipation Under Treatment With Naloxegol
Recruiting NCT05149833 - European Study of Opioid Induced Constipation
Completed NCT01186770 - A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain Phase 3
Completed NCT02270983 - Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain Phase 2
Completed NCT00640146 - Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures Phase 2
Terminated NCT01696643 - Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation Phase 3
Terminated NCT00399659 - Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain. Phase 3
Terminated NCT01901302 - Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation Phase 3
Withdrawn NCT00858754 - Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects Phase 4
Completed NCT05770960 - Colonic Motor Patterns in Healthy Volunteers Phase 4
Terminated NCT01384292 - Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain Phase 3
Completed NCT00672477 - Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness Phase 4
Recruiting NCT03687268 - Naloxone HCl PR Tablets in Patients With Opioid Induced Constipation Phase 3
Completed NCT00672139 - Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness Phase 4
Terminated NCT01901341 - The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation Phase 3
Recruiting NCT03720613 - Risk of Major Adverse Cardiovascular Events for Naldemedine and Other Medications for Opioid Induced Constipation in Adults With Chronic Non-Cancer Pain
Completed NCT01368562 - Compassionate Use Study of Methylnaltrexone N/A
Completed NCT01040637 - A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation Phase 1/Phase 2
Recruiting NCT05133076 - Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications Phase 2